Mersana Therapeutics, Inc. Announce Executive Changes Effective from September 30, 2019
July 26, 2019 at 09:02 pm
Share
On July 26, 2019, Mersana Therapeutics, Inc. announced that Wayne Foster, Vice President of Finance and the Company's principal accounting officer, would be departing the Company as of September 30, 2019, and in connection with that departure, Mr. Foster will stop serving as the Company's principal accounting officer following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, timing for which will be publicly announced in the near term. As of that date, Ashish Mandelia, age 45, who was appointed Vice President, Controller in July 2019, will become the Company's new principal accounting officer. Mr. Mandelia previously served as Senior Director, Technical Accounting at TESARO, Inc., where he worked for more than two years. Prior to joining TESARO, Inc., Mr. Mandelia held roles of increasing responsibility over the course of 12 years at PwC in its Boston and London offices.
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
MERSANA THERAPEUTICS, INC. 
